Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters
Duquesne Family Office's billionaire chief sold every share of Wall Street's hottest artificial intelligence (AI) stock in favor of a drugmaker whose shares have surged 142% in two years.
There's nothing more valuable on Wall Street than data, and investors rarely have to dig to find something that's pertinent to the U.S. economy, the stock market, or their specific portfolio holdings.
The issue is that between earnings season -- the six-week period where many of America's most-influential public businesses report their operating results each quarter -- and near-daily economic data releases, something important can easily fall through the cracks or slide under the radar of investors. A perfect example being the filing of Form 13Fs with the Securities and Exchange Commission last month.
No later than 45 calendar days following the end to a quarter, institutional investors with at least $100 million in assets under management are required to file a 13F. This form concisely details which stocks, exchange-traded funds (ETFs), and select options the market's brightest money managers bought and sold in the latest quarter. In other words, it can help investors spot the stocks and trends captivating the attention of the world's best investors.
